Research programme : cancer immunotherapeutics and companion diagnostics - Bristol-Myers Squibb/QIAGEN
Latest Information Update: 28 Jul 2021
At a glance
- Originator Bristol-Myers Squibb; QIAGEN
- Class Antineoplastics; Diagnostic agents; Immunotherapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer